Immune checkpoint inhibitors, especially those targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), proved effective in treating various solid tumors, such as melanoma, renal cell carcinoma and non-small cell lung cancer. This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.